| 1.79 -0.11 (-5.57%) | 10-07 13:30 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.3 | 1-year : | 2.52 |
| Resists | First : | 1.97 | Second : | 2.16 |
| Pivot price | 1.88  |
|||
| Supports | First : | 1.66 | Second : | 1.38 |
| MAs | MA(5) : | 1.85 |
MA(20) : | 1.9 |
| MA(100) : | 2.18 |
MA(250) : | 2.41 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 17.6 |
D(3) : | 18.2 |
| RSI | RSI(14): 46.7 |
|||
| 52-week | High : | 4.42 | Low : | 1.54 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LIXT ] has closed above bottom band by 44.7%. Bollinger Bands are 25.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.95 - 1.96 | 1.96 - 1.97 |
| Low: | 1.83 - 1.84 | 1.84 - 1.85 |
| Close: | 1.83 - 1.85 | 1.85 - 1.86 |
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.
Sun, 29 Sep 2024
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.22% - MSN
Wed, 11 Sep 2024
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing - AccessWire
Tue, 27 Aug 2024
LIXT stock touches 52-week low at $1.55 amid market fluctuations - Investing.com
Mon, 26 Aug 2024
First Patient Dosed with LIXTE’s LB-100 in New Clinical - GlobeNewswire
Fri, 14 Jun 2024
Lixte Biotechnology (LIXT) Sees Stock Boost Following Key European Collaboration - Catching News
Fri, 14 Jun 2024
LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 20.4 (%) |
| Held by Institutions | 7.9 (%) |
| Shares Short | 35 (K) |
| Shares Short P.Month | 10 (K) |
| EPS | -1.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.57 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -87.4 % |
| Return on Equity (ttm) | -163.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -1.09 |
| PEG Ratio | 0 |
| Price to Book value | -3.34 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|